Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 868

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9B
Chunk 868
---
-cash investing and financing activities: 

    Offering costs included in accrued offering costs 
    $56,065 
  
    Deferred offering costs paid via promissory note – related party 
    $126,169 
  
    Prepaid services contributed by Sponsor through promissory note- related party 
    $3,640 

The accompanying notes are an integral part
of the financial statements.

F-6

DRUGS MADE IN AMERICA ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2024

NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS
OPERATIONS

Drugs Made In America Acquisition Corp. (the “Company”)
is a blank check company newly incorporated in the Cayman Islands on May 23, 2024. The Company was incorporated for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination
with one or more businesses (the “Business Combination”). The Company has not selected any Business Combination target
and it has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination
target with respect to an initial Business Combination.

Although the Company may acquire a business in
any industry, it intends to focus on companies in the pharmaceutical industry. The Company is an early stage and emerging growth company
and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of December 31, 2024, the Company had not commenced
any operations. All activity for the period from May 23, 2024 (inception) through December 31, 2024 relates to the Company’s
formation and the initial public offering (“Initial Public Offering”), which is described below. The Company will not generate
any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statement for the Company’s
Initial Public Offering was declared effective on January 7, 2025 and the post-effective amendment to the registration statement was declared
effective on January 27, 2025. On January 29, 2025, the Company consummated the Initial Public Offering of 20,000,000 units (the “Units”
and